Wells Fargo & Company Evotec Se Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EVO
# of Institutions
32Shares Held
2.86MCall Options Held
0Put Options Held
0-
Wellington Management Group LLP Boston, MA2.03MShares$9.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny192KShares$877,1980.0% of portfolio
-
Mediolanum International Funds LTD Dublin 1, L2140KShares$642,9540.01% of portfolio
-
Morgan Stanley New York, NY122KShares$557,8890.0% of portfolio
-
Dcf Advisers, LLC Greenwich, CT115KShares$526,4840.3% of portfolio
About Evotec SE
- Ticker EVO
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 353,904,992
- Market Cap $1.62B
- Description
- Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare di...